The Cytomegalovirus Infections market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM CMV Infections market size from 2018 to 2030. The Report also covers current CMV Infections treatment practice, market drivers, market barriers, SWOT analysis, reimbursement, and market access, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Cytomegalovirus (CMV) Infections Overview
Cytomegalovirus infection (CMV) is a viral infection that rarely causes obvious illness. The virus that causes CMV is part of the herpes virus family and, like other herpes viruses, may become dormant for a period of time and then be reactivated. CMV affects young children mainly, but it is estimated that by age 30 in the United States, half of all adults are, or have been, infected. The virus can pass from an infected, pregnant mother to her child through the shared blood supply (umbilical cord).
Request free sample copy- https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-market
List of regions covered in the report
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
List of companies involved in the report
- Roche
- Clinigen Group plc
- CSL Behring
- And many others
Cytomegalovirus Infections Symptoms
CMV Infections may cause symptoms soon after infection and can also remain dormant (inactive) in various tissues for life. Various stimuli can reactivate the dormant CMV Infections, resulting in virus growth which can sometimes cause disease. The lungs, gastrointestinal tract, brain, spinal cord, or eyes may be infected.
Cytomegalovirus Infections Diagnosis
Most of the CMV infections go undiagnosed because the virus causes little to no symptoms. When a person is infected with CMV, antibodies (proteins) to the virus called IgM and/or IgG anti-CMV antibodies develop and stay in the body for the rest of the person's life. Once a CMV infection is suspected, a doctor conducts tests to detect the virus in body fluids or tissues. In newborns, the diagnosis is usually made by culturing the urine.
A blood test to detect the antibodies will be positive if the person has had a CMV infection. If the antibody test is negative, the person is considered to be uninfected with CMV. Serology tests are useful for determining whether a patient has had CMV infection in the past or not, by the presence or absence of CMV IgG.
Cytomegalovirus Infections Treatment
There are various approaches for the prevention of CMV. Major strategies for prevention are:
1. Antiviral prophylaxis
2. Pre-emptive therapy
Antiviral drugs for CMV prophylaxis are valganciclovir and oral or intravenous ganciclovir. For kidney recipients, valacyclovir is an alternative. In selected patient populations (heart and lung recipients), immunoglobulin preparations are occasionally used as an adjunct in combination with antiviral drugs. Acyclovir should NOT be used for anti-CMV prophylaxis. Infection with ganciclovir-resistant CMV has been associated with increased morbidity and mortality in SOT patients. The incidence is highest among lung transplant recipients.
Genotypic testing should be performed when resistance is suspected. In patients with low-level resistance to ganciclovir conferred by UL97 mutation, an increased dose of IV ganciclovir may be used (up to 10 mg/kg twice daily). Foscarnet is the preferred drug in high-level ganciclovir resistance, though cidofovir has been used occasionally. Reducing immunosuppression or switching from calcineurin to mTOR inhibitors such as sirolimus may be helpful. Experimental antiviral drugs that are being developed or considered for use in CMV resistant to ganciclovir, foscarnet, and cidofovir are letermovir and CMX-001 (orally available lipid prodrug of cidofovir).
Cytomegalovirus Infections Emerging Drugs
- Triplex: Helocyte
- V160: Merck
- And many others
Cytomegalovirus Infections Market Outlook
Cytomegalovirus (CMV), is extremely common worldwide. The global burden of Cytomegalovirus Infection has increased over the year (approximately 50% of US adults are infected with CMV). Among the seven major markets, the United States has reported having a maximum number of CMV patients. In most individuals, primary infection with CMV is asymptomatic, with the infected host showing no signs or symptoms of the disease.
Healthy people who are infected with CMV usually do not require medical treatment. Medications are available to treat CMV infection in people who have weakened immune systems and babies with signs of congenital CMV. For babies with signs of congenital CMV infection at birth, antiviral medications may improve hearing and developmental outcomes.
Cytomegalovirus Infections Market Insights
Cytomegalovirus (CMV), is extremely common worldwide. Global burden of Cytomegalovirus Infection has increased over the year (approximately 50% of the US adults are infected with CMV). In most individuals, primary infection with CMV is asymptomatic, with the infected host showing no signs or symptoms of the disease.
Cytomegalovirus Infections Market Report
The market is expected to grow by factors like an increase in the patient pool, expected entry of emerging therapies, i.e., such as V160, mRNA-1647, HB-101, and deeper penetration in the United states markets.
Cytomegalovirus Infections Market Report Scope
- The report covers the descriptive overview of CMV Infections, explaining its causes, symptoms, pathophysiology, genetic basis, and currently available therapies.
- Comprehensive insight has been provided into the CMV Infections epidemiology and treatment.
- Additionally, an all-inclusive account of both the current and emerging therapies for CMV Infections is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.
- A detailed review of the CMV Infections market; historical and forecasted is included in the report, covering the 7MM drug outreach.
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM CMV Infections market.
Request free sample copy- https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-market
Table of content
1. Key Insights
2. Executive Summary of Cytomegalovirus (CMV) Infection
3. Competitive Intelligence Analysis for Cytomegalovirus (CMV) Infection
4. Cytomegalovirus (CMV) Infection: Market Overview at a Glance
5. Cytomegalovirus (CMV) Infection: Disease Background and Overview
6. Patient Journey
7. Cytomegalovirus (CMV) Infection Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Cytomegalovirus (CMV) Infection Treatment
11. Marketed Products
12. Emerging Therapies
13. Cytomegalovirus (CMV) Infection: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Cytomegalovirus (CMV) Infection
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Why should you buy this report?
- The report will help in developing business strategies by understanding trends shaping and driving CMV Infections.
- To understand the future market competition in the CMV Infections market and Insightful review of the key market drivers and barriers.
- Organize sales and marketing efforts by identifying the best opportunities for CMV Infections in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
- Organize sales and marketing efforts by identifying the best opportunities for the CMV Infections market.
- To understand the future market competition in the CMV Infections market.
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
